Cargando…

Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction

To assess whether beta-blocker use is associated with cardiovascular events and mortality in patients with heart failure with preserved ejection fraction (HFpEF), this study analyzed the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial data using Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsujimoto, Tetsuro, Kajio, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015007/
https://www.ncbi.nlm.nih.gov/pubmed/29934526
http://dx.doi.org/10.1038/s41598-018-27799-y
_version_ 1783334306425339904
author Tsujimoto, Tetsuro
Kajio, Hiroshi
author_facet Tsujimoto, Tetsuro
Kajio, Hiroshi
author_sort Tsujimoto, Tetsuro
collection PubMed
description To assess whether beta-blocker use is associated with cardiovascular events and mortality in patients with heart failure with preserved ejection fraction (HFpEF), this study analyzed the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial data using Cox proportional hazard models. Adjusted HRs for composite cardiovascular events in all patients and in patients without previous MI were significantly higher for those on beta-blockers than for those not on beta-blockers (Hazard ratio [HR] for all patients 1.23, 95% confidence interval [95% CI] 1.02–1.49; HR for patients without previous MI 1.35, 95% CI 1.08–1.70), whereas that for patients with previous MI was not significantly different (HR 1.06, 95% CI 0.74–1.54). Additionally, cardiovascular event risk in propensity score-matched patients without previous MI was significantly higher in those on beta-blockers than in those not on beta-blockers. Risks of all-cause death, major cardiovascular events, and heart failure hospitalization were significantly higher in those on beta-blockers than in those not on beta-blockers. Beta-blocker use in HFpEF patients, particularly those without previous MI, was associated with increased risk of unfavorable cardiovascular events.
format Online
Article
Text
id pubmed-6015007
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60150072018-07-06 Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction Tsujimoto, Tetsuro Kajio, Hiroshi Sci Rep Article To assess whether beta-blocker use is associated with cardiovascular events and mortality in patients with heart failure with preserved ejection fraction (HFpEF), this study analyzed the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial data using Cox proportional hazard models. Adjusted HRs for composite cardiovascular events in all patients and in patients without previous MI were significantly higher for those on beta-blockers than for those not on beta-blockers (Hazard ratio [HR] for all patients 1.23, 95% confidence interval [95% CI] 1.02–1.49; HR for patients without previous MI 1.35, 95% CI 1.08–1.70), whereas that for patients with previous MI was not significantly different (HR 1.06, 95% CI 0.74–1.54). Additionally, cardiovascular event risk in propensity score-matched patients without previous MI was significantly higher in those on beta-blockers than in those not on beta-blockers. Risks of all-cause death, major cardiovascular events, and heart failure hospitalization were significantly higher in those on beta-blockers than in those not on beta-blockers. Beta-blocker use in HFpEF patients, particularly those without previous MI, was associated with increased risk of unfavorable cardiovascular events. Nature Publishing Group UK 2018-06-22 /pmc/articles/PMC6015007/ /pubmed/29934526 http://dx.doi.org/10.1038/s41598-018-27799-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Tsujimoto, Tetsuro
Kajio, Hiroshi
Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
title Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
title_full Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
title_fullStr Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
title_full_unstemmed Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
title_short Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
title_sort beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015007/
https://www.ncbi.nlm.nih.gov/pubmed/29934526
http://dx.doi.org/10.1038/s41598-018-27799-y
work_keys_str_mv AT tsujimototetsuro betablockeruseandcardiovasculareventriskinpatientswithheartfailurewithpreservedejectionfraction
AT kajiohiroshi betablockeruseandcardiovasculareventriskinpatientswithheartfailurewithpreservedejectionfraction